Identification of potential synthetic lethal genes to p53 using a computational biology approach

BackgroundIdentification of genes that are synthetic lethal to p53 is an important strategy for anticancer therapy as p53 mutations have been reported to occur in more than half of all human cancer cases. Although genome-wide RNAi screening is an effective approach to finding synthetic lethal genes, it is costly and labor-intensive.MethodsTo illustrate this approach, we identified potentially druggable genes synthetically lethal for p53 using three microarray datasets for gene expression profiles of the NCI-60 cancer cell lines, one next-generation sequencing (RNA-Seq) dataset from the Cancer Genome Atlas (TCGA) project, and one gene expression data from the Cancer Cell Line Encyclopedia (CCLE) project. We selected the genes which encoded kinases and had significantly higher expression in the tumors with functional p53 mutations (somatic mutations) than in the tumors without functional p53 mutations as the candidates of druggable synthetic lethal genes for p53. We identified important regulatory networks and functional categories pertinent to these genes, and performed an extensive survey of literature to find experimental evidence that support the synthetic lethality relationships between the genes identified and p53. We also examined the drug sensitivity difference between NCI-60 cell lines with functional p53 mutations and NCI-60 cell lines without functional p53 mutations for the compounds that target the kinases encoded by the genes identified.ResultsOur results indicated that some of the candidate genes we identified had been experimentally verified to be synthetic lethal for p53 and promising targets for anticancer therapy while some other genes were putative targets for development of cancer therapeutic agents.ConclusionsOur study indicated that pre-screening of potential synthetic lethal genes using gene expression profiles is a promising approach for improving the efficiency of synthetic lethal RNAi screening.

[1]  Varda Rotter,et al.  Transcriptional control of the proliferation cluster by the tumor suppressor p53. , 2010, Molecular bioSystems.

[2]  F. Posas,et al.  A human homolog of the yeast Ssk2/Ssk22 MAP kinase kinase kinases, MTK1, mediates stress‐induced activation of the p38 and JNK pathways , 1997, The EMBO journal.

[3]  J. Koivunen,et al.  Protein kinase C (PKC) family in cancer progression. , 2006, Cancer letters.

[4]  S. Akira,et al.  DRAKs, Novel Serine/Threonine Kinases Related to Death-associated Protein Kinase That Trigger Apoptosis* , 1998, The Journal of Biological Chemistry.

[5]  Funda Meric-Bernstam,et al.  Targeting the mTOR signaling network for cancer therapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  K. Wiman.  Restoration of wild-type p53 function in human tumors: strategies for efficient cancer therapy. , 2007, Advances in cancer research.

[7]  K. Kinzler,et al.  A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53 , 2009, Proceedings of the National Academy of Sciences.

[8]  Christopher C. Porter,et al.  ATM and MET kinases are synthetic lethal with non-genotoxic activation of p53 , 2012, Nature chemical biology.

[9]  William C Reinhold,et al.  CellMiner: a relational database and query tool for the NCI-60 cancer cell lines , 2009, BMC Genomics.

[10]  Michael J. Emanuele,et al.  A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene , 2009, Cell.

[11]  Galina Selivanova,et al.  Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound , 2002, Nature Medicine.

[12]  Hongjuan Zhao,et al.  TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer , 2007, Breast Cancer Research.

[13]  N. Sonenberg,et al.  Upstream and downstream of mTOR. , 2004, Genes & development.

[14]  A. Ullrich,et al.  Regulation of Akt(ser473) phosphorylation by Choline kinase in breast carcinoma cells , 2009, Molecular Cancer.

[15]  Zhaohui Feng,et al.  p53 regulation of the IGF-1/AKT/mTOR pathways and the endosomal compartment. , 2010, Cold Spring Harbor perspectives in biology.

[16]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[17]  Shile Huang,et al.  Targeting mTOR signaling for cancer therapy. , 2003, Current opinion in pharmacology.

[18]  James R Bischoff,et al.  A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations , 2011, Nature Structural &Molecular Biology.

[19]  J. Minna,et al.  Distinct Epidermal Growth Factor Receptor and KRAS Mutation Patterns in Non–Small Cell Lung Cancer Patients with Different Tobacco Exposure and Clinicopathologic Features , 2006, Clinical Cancer Research.

[20]  T. Roberts,et al.  Surveillance mechanism linking Bub1 loss to the p53 pathway , 2007, Proceedings of the National Academy of Sciences.

[21]  Erich A. Nigg,et al.  Polo-like kinases and the orchestration of cell division , 2004, Nature Reviews Molecular Cell Biology.

[22]  A. Albino,et al.  Mutant human tumor suppressor p53 modulates the activation of mitogen‐activated protein kinase and nuclear factor‐κB, but not c‐Jun N‐terminal kinase and activated protein‐1 , 2006, Molecular carcinogenesis.

[23]  Yingdong Zhao,et al.  Analysis of Gene Expression Data Using BRB-Array Tools , 2007, Cancer informatics.

[24]  S. Fu,et al.  A novel Aurora-A-mediated phosphorylation of p53 inhibits its interaction with MDM2. , 2013, Biochimica et biophysica acta.

[25]  V. Raman,et al.  RNA interference-mediated choline kinase suppression in breast cancer cells induces differentiation and reduces proliferation. , 2005, Cancer research.

[26]  W. Pickl,et al.  Polo-like kinase-1 as a novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of small interfering RNA and the Polo-like kinase-1 targeting drug BI 2536 , 2011, Haematologica.

[27]  Charlotta Lindvall,et al.  Cdc7-Dbf4 kinase overexpression in multiple cancers and tumor cell lines is correlated with p53 inactivation. , 2008, Neoplasia.

[28]  H. Kotani,et al.  Mutant p53 induces the GEF-H1 oncogene, a guanine nucleotide exchange factor-H1 for RhoA, resulting in accelerated cell proliferation in tumor cells. , 2006, Cancer research.

[29]  A. Montagnoli,et al.  Cdc7 Inhibition Reveals a p53-Dependent Replication Checkpoint That Is Defective in Cancer Cells , 2004, Cancer Research.

[30]  S. Geley,et al.  Cyclin-Dependent Kinase 16/PCTAIRE Kinase 1 Is Activated by Cyclin Y and Is Essential for Spermatogenesis , 2011, Molecular and Cellular Biology.

[31]  L. Loeb,et al.  Mutations in the KRAS2 oncogene during progressive stages of human colon carcinoma. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[32]  Charles M Perou,et al.  Gene expression patterns associated with p53 status in breast cancer , 2006, BMC Cancer.

[33]  R. Moon,et al.  Mindbomb 1, an E3 ubiquitin ligase, forms a complex with RYK to activate Wnt/β-catenin signaling , 2011, The Journal of cell biology.

[34]  P. Lazo,et al.  The human vaccinia-related kinase 1 (VRK1) phosphorylates threonine-18 within the mdm-2 binding site of the p53 tumour suppressor protein , 2000, Oncogene.

[35]  H. Masai,et al.  Functions of mammalian Cdc7 kinase in initiation/monitoring of DNA replication and development. , 2003, Mutation research.

[36]  V. Rotter,et al.  Transcription regulation by mutant p53 , 2007, Oncogene.

[37]  T. Yen,et al.  p53-dependent apoptosis in response to spindle damage is linked to loss of Bub1 , 2009, Cancer biology & therapy.

[38]  T. Eguchi,et al.  RB silencing compromises the DNA damage-induced G2/M checkpoint and causes deregulated expression of the ECT2 oncogene , 2007, Oncogene.

[39]  K. Kohn,et al.  CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. , 2012, Cancer research.

[40]  W. Kaelin.  The Concept of Synthetic Lethality in the Context of Anticancer Therapy , 2005, Nature Reviews Cancer.

[41]  H. Mackay,et al.  Targeting the protein kinase C family: are we there yet? , 2007, Nature Reviews Cancer.

[42]  Giulia Piaggio,et al.  Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. , 2006, Cancer cell.

[43]  H. Kotani,et al.  Synthetic lethal interactions for the development of cancer therapeutics: biological and methodological advancements , 2010, Human Genetics.

[44]  D. Shibata,et al.  Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes , 1988, Cell.

[45]  J. Peters,et al.  The Small-Molecule Inhibitor BI 2536 Reveals Novel Insights into Mitotic Roles of Polo-like Kinase 1 , 2007, Current Biology.

[46]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[47]  G. Bossi,et al.  BASIC SCIENCE REVIEW , 2007 .

[48]  William Arbuthnot Sir Lane,et al.  A serine kinase regulates intracellular localization of splicing factors in the cell cycle , 1994, Nature.

[49]  E. Nigg,et al.  Plk4-induced centriole biogenesis in human cells. , 2007, Developmental cell.

[50]  S. Shieh,et al.  TTK/hMps1 Mediates the p53-Dependent Postmitotic Checkpoint by Phosphorylating p53 at Thr18 , 2009, Molecular and Cellular Biology.

[51]  M. Mann,et al.  A systematic RNAi synthetic interaction screen reveals a link between p53 and snoRNP assembly , 2011, Nature Cell Biology.

[52]  R. Medema,et al.  Targeting the Mitotic Checkpoint to Kill Tumor Cells , 2010, Hormones & cancer.

[53]  H. Saito,et al.  SAPK pathways and p53 cooperatively regulate PLK4 activity and centrosome integrity under stress , 2013, Nature Communications.

[54]  T. Jacks,et al.  Restoration of p53 function leads to tumour regression in vivo , 2007, Nature.

[55]  A. Chinnaiyan,et al.  Functionally Recurrent Rearrangements of the MAST Kinase and Notch Gene Families in Breast Cancer , 2011, Nature Medicine.

[56]  J. Roh,et al.  p53-Reactivating small molecules induce apoptosis and enhance chemotherapeutic cytotoxicity in head and neck squamous cell carcinoma. , 2011, Oral oncology.

[57]  A. Levine,et al.  The coordinate regulation of the p53 and mTOR pathways in cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[58]  David Gallego-Ortega,et al.  Choline kinase as a link connecting phospholipid metabolism and cell cycle regulation: implications in cancer therapy. , 2008, The international journal of biochemistry & cell biology.

[59]  Eun-Kyoung Breuer,et al.  Mitotic Kinases and p53 Signaling , 2012, Biochemistry research international.

[60]  Xiaoqi Liu,et al.  Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[61]  Richard Sainsbury,et al.  Targeting DNA replication before it starts: Cdc7 as a therapeutic target in p53-mutant breast cancers. , 2010, The American journal of pathology.

[62]  P. Kamath,et al.  Mutations in PRKCSH cause isolated autosomal dominant polycystic liver disease. , 2003, American journal of human genetics.

[63]  J. Sebolt-Leopold,et al.  Knockdown of Chk1, Wee1 and Myt1 by RNA Interference Abrogates G2 Checkpoint and Induces Apoptosis , 2004, Cancer biology & therapy.

[64]  A. Neri,et al.  Restoration of the transcription activation function to mutant p53 in human cancer cells. , 1996, Oncogene.

[65]  D. Schmatz,et al.  Integrated genomic and pharmacological approaches to identify synthetic lethal genes as cancer therapeutic targets. , 2008, Current molecular medicine.

[66]  C. Cordon-Cardo,et al.  Gene transfer of wild-type p53 results in restoration of tumor-suppressor function in a medulloblastoma cell line , 1995, Neurology.

[67]  A. Ramírez de Molina,et al.  Differential Role of Human Choline Kinase α and β Enzymes in Lipid Metabolism: Implications in Cancer Onset and Treatment , 2009, PloS one.

[68]  M. Baccarini,et al.  Raf kinases in cancer–roles and therapeutic opportunities , 2011, Oncogene.

[69]  Eytan Domany,et al.  The promoters of human cell cycle genes integrate signals from two tumor suppressive pathways during cellular transformation , 2005, Molecular systems biology.

[70]  Wei Zhang,et al.  Centrosome-associated regulators of the G2/M checkpoint as targets for cancer therapy , 2009, Molecular Cancer.

[71]  Anindita Das,et al.  Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes , 2004, Oncogene.

[72]  P. Lazo,et al.  Kinetic properties of p53 phosphorylation by the human vaccinia-related kinase 1. , 2002, Archives of biochemistry and biophysics.

[73]  Gen Sheng Wu.  The functional Interactions Between the MAPK and p53 Signaling Pathways , 2004, Cancer biology & therapy.

[74]  D. Canaani.  Methodological approaches in application of synthetic lethality screening towards anticancer therapy , 2009, British Journal of Cancer.

[75]  J. Berlin,et al.  Aurora Kinase Inhibitors - Rising Stars in Cancer Therapeutics? , 2010, Molecular Cancer Therapeutics.

[76]  M. Davidson,et al.  Automated Screening of Microtubule Growth Dynamics Identifies MARK2 as a Regulator of Leading Edge Microtubules Downstream of Rac1 in Migrating Cells , 2012, PloS one.

[77]  Joel Greshock,et al.  Sensitivity of Cancer Cells to Plk1 Inhibitor GSK461364A Is Associated with Loss of p53 Function and Chromosome Instability , 2010, Molecular Cancer Therapeutics.

[78]  K. Coombes,et al.  Identification of Cell Cycle Regulatory Genes as Principal Targets of p53-mediated Transcriptional Repression* , 2006, Journal of Biological Chemistry.

[79]  J. Ruderman,et al.  Aurora A, Meiosis and Mitosis , 2004, Biology of the cell.

[80]  T. Ouchi,et al.  Sustained activation of Ras/Raf/mitogen-activated protein kinase cascade by the tumor suppressor p53. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[81]  M. Wilkinson,et al.  Control of the eukaryotic cell cycle by MAP kinase signaling pathways , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[82]  Bei Wang,et al.  The p53 response element and transcriptional repression , 2010, Cell cycle.